References: Kaposi sarcoma detailed guide
Ambiner RF, Wagner-Johnston ND. HIV-associated malignancies. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, PA: Elsevier; 2008: 1061−1071.
Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer. 2006;107:2282−2290.
Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi’s sarcoma. Lancet Oncol. 2007;8:167−176.
Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973-1998. J Natl Cancer Inst. 2002;94:1204−1210.
Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007;196:199−207.
Geraminejad P, Memar O, Aronson I, et al. Kaposi’s sarcoma and other manifestations of human herpesvirus 8. J Am Acad Dermatol. 2002;47:641−655.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: Epidemiology and risk factors. Cancer. 2000;88:500−517.
Krown SE, Testa MA, Huang J. AIDS-related Kaposi’s sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085−3092.
Lanternier F, Lebbé C, Schartz N, et al. Kaposi’s sarcoma in HIV-negative men having sex with men. AIDS. 2008;22:1163−1168.
Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood. 2007;110:4165−4171.
Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006;107:4650−4657.
Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2000;18:2593−2602.
Lodi S, Guiguet M, Costagliola D, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102:784−792.
Mocroft A, Kirk O, Clumeck N. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2004. Cancer. 2004;100:2644−2654.
Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi’s sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876−2882.
National Cancer Institute Physician Data Query (PDQ): Kaposi sarcoma treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/kaposis/HealthProfessional on November 19, 2012.
Serraino D, De Paoli A, Zucchetto A, et al. The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiol. 2010;34:257−261.
Strother RM, Gregory KM, Pastakia SD, et al. Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi’s sarcoma in western Kenya. Oncology. 2010;78:5−11.
Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012;30:1476−1483.
Yarchoan R, Uldrick TS, Little RF. AIDS-related malignancies. In: DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
Last Medical Review: 02/20/2013
Last Revised: 02/20/2013